Technologies

AIDD is an integrated tool and a radically new way to discovery new drugs for neurodegenerative diseases (Alzheimer’s, Epilepsy, Ageing, etc.).

Time-correlated single photon counting (TCSPC) is regarded as the “gold-standard” method for fluorescence lifetime measurements. However, TCSPC requires using highly sensitive detectors, not suitable for measurements under bright light conditions, thereby making the use impractical in clinical settings. The invention described here solves this problem by synchronizing the fluorescence detection with an external light source.

The Biocrystal Facility, a large multidisciplinary laboratory established at the Institute of Molecular Biology and Pathology (IBPM) of CNR, in collaboration with the Biochemistry Department of Sapienza University aims at supporting the italian scientists and the pharmaceutical companies in the research to find new drug and vaccine against the endemic and epidemic diseases through structure-based drug design.

The compact-GC platform is a MEMS-based analytical module for the purge&trap pre-concentration and (gas)-chromatographic separation of a sample. The two analytical MEMS (pre-concentrator and GC column) are interconnected by means of a MEMS microfluidic manifold. The microfluidic manifold interconnects the analytical MEMS, but it also acts as injector through the integrated micro-valves.

The virtual dynamic docking, carried out in the MOLBD3 lab of the Institute of Biophysics, allows the identification of new drugs through the structural information deriving from the study of target proteins, responsible for some human pathologies. In particular, we screen drugs or small molecules (commercial/own libraries) against known protein sites, surface cavities, surfaces of protein-protein interactions (fixed/rigid hotspots) or structural transition states (dynamic hotspots).

Method for extracting, with high yield, phycobiliproteins from cyanobacterial and/or algal biomass, obtaining aqueous extracts characterized by high concentration of pigments (4-5 mg/mL)  and a purity, at least equal to food/cosmetic grade (P≥2).

We propose a portable chemical analysis system capable of identifying chemical substances at trace concentrations (sub-ppm), even in case of a complex matrix of interfering species.

In the last years, genetics played a strategic role in the identification of therapeutic targets for complex diseases. Genetic studies identified thousands of variants contributing to disease onset and/or to the influence of measurable features (phenotypes) impacting health. The mechanism of action by which they modulate diseases and phenotypes is still unknown for the vast majority.

The procedure enables the fabrication of nanocomposite membranes filled with suitable amounts of exfoliated bidimensional crystals. These are obtained with an advanced wet-jet milling technique, which provides desired thickness and lateral size of nanofillers through the pulverization and colloidal homogenization of bulk nanomaterials. The bidimensional crystals are dispersed in fluids and suitably delivered inside polymeric matrixes exhibiting a singular morphology.

WembraneX is an Italian start-up born with the ambition to make a significant contribution to UN Sustainable Goal 6 - Ensure Access to Clean Water and Sanitation for all by 2030.

This technology describe the synthesis of cross-linked polymeric materials in the form of macroporous gels based on poly (2-hydroxyethyl methacrylate), capable of sequestering the anticoagulant heparin from aqueous solutions, physiological solutions and biological fluids. They are morphologically elastic and mechanically stable materials, and show high specificity and selectivity for heparin as demonstrated by the negligible adsorption of specific blood proteins such as antithrombin III, albumin and total proteins.

The development of an innovative screening platform of natural marine extracts guided by biological assays represents one of the main products developed within the Antitumor Drugs and Vaccines from the SEA (ADViSE) project which aims to provide a new vision in Drug Discovery processes.

The study of proteins is typically limited to notions, sometimes with the aid of virtual 3D models, obtained from visualization programs. A knowledge of this type, although useful, limits the ability to acquire a more direct knowledge, almost never leads to awareness of dimensions, and is particularly difficult for those who do not have a strong capacity for three-dimensional imagination.

We present a technology for the multiscale isolation (analytical-laboratory-production) of Extracellular Vesicles (VE), which overcomes the limitations of the currently available methods. As opposed to traditional "affinity-based" systems that exploit antibodies, our technology represents a radical paradigm shift in the development of affinity probes for vesicles, i.e.